ST. PAUL, Minn., Aug. 5 /PRNewswire/ -- Pharmacy spending for Prime Therapeutics (Prime) and its Blue Cross and Blue
The analysis found spending on traditional drugs increased just 1.8 percent in 2009, well below the 4 percent rate of inflation among those drugs. Spending on specialty medications – which are used to treat complex medical conditions such as multiple sclerosis, hemophilia and rheumatoid arthritis – increased 13 percent. Prime's drug trend compares favorably to its national competitors who reported 2009 drug spend increases averaging 4.5 percent—with some as high as 6.4 percent—by reporting on a select portion of their accounts.
"Prime's drug trend results represent our entire Commercial book of business—in contrast to major competitors that report on a narrower subset of their accounts," said Steve Blumenfield, Prime's Chief Marketing Officer. "Our approach clearly demonstrates that excellent cost of care and complete transparency can be achieved, together."
Prime's approach, in concert with its Blue Cross and Blue Shield owners and clients, is to deliver health-oriented pharmacy benefits at the lowest possible cost:
"Working with our Blue Cross partners, we have once again achieved one of the best drug trends in the industry," said Eric Elliott, president and CEO, Prime. "We've proven that Prime delivers industry leading pharmacy benefit management focused on innovative pharmacy solutions, increased use of generics and greater adherence among our members. Our focus on improving member health, not profits, means greater quality of care and increased savings for both members and plan sponsors."
Key findings in Drug Trend Insights report include:
"For Prime, drug trend isn't just about reducing costs, but about providing the greatest value for our members and clients," said Elliott. "Helping patients access the medications that are shown to improve their health, and helping them stick to those medications, is one of the best ways to reduce overall health care spending and provide the greatest value for every pharmacy dollar."
Drug Trend Insights is Prime's annual report on the factors that influence prescription drug spending, along with a review of its efforts to control cost increases while improving health care quality. A full copy of the 2010 Drug Trend Insights report is available at www.primetherapeutics.com.
Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 17 million covered lives*, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minn., Prime Therapeutics is collectively owned by 12 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at www.primetherapeutics.com.
*As of January 1, 2011
(1) Competitor average derived from drug trends reported by the top three publicly-owned PBMs. Sources: CVS Caremark Insights 2010; Express Scripts 2009 Drug Trend Report; Medco 2010 Drug Trend Report
SOURCE Prime Therapeutics
Subscribe to our Free Newsletters!
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...
Ecchymosis is a flat, discolored patch of skin that occurs when there is bleeding underneath; it is ...
Age related macular degeneration is a disease of the elderly, wherein the macula or the central ...View All